TS 23
Alternative Names: CSL-301; DS-9231; Stromab; TS23Latest Information Update: 28 Jul 2025
At a glance
- Originator Translational Sciences
- Developer Daiichi Sankyo Company; Translational Sciences
- Class Anti-ischaemics; Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Antiplasmin inhibitors; Fibrinolytic agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ischaemic stroke; Pulmonary embolism
- No development reported Myocardial infarction; Thrombosis; Venous thrombosis
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Myocardial-infarction in USA (Parenteral)
- 28 Jul 2025 No recent reports of development identified for phase-I development in Venous-thrombosis in USA (Parenteral)
- 18 Mar 2024 Translational Sciences initiates enrolment in a phase II SISTER trial for Ischaemic stroke in USA (NCT05948566)